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Abstract
Background: The Bridging the Age Gap in Breast Cancer research programme sought to improve treatment decision-
making for older women with breast cancer by developing and testing, in a cluster randomised trial (n = 1339
patients), two decision support interventions (DESIs). Both DESIs were used in the intervention arm and each
comprised an online risk prediction model, brief decision aid and information booklet. One DESI supported the
decision to have either primary endocrine therapy (PET) or surgery with adjuvant therapies and the second supported
the decision to have adjuvant chemotherapy after surgery or not.
Methods: Sixteen sites were randomly selected to take part in the process evaluation. Multiple methods of data
collection were used. Medical Research Council (MRC) guidelines for the evaluation of complex interventions were
used.
Results: Eighty-two patients, mean age 75.5 (range 70–93), provided data for the process evaluation. Seventy-three
interviews were completed with patients. Ten clinicians from six intervention sites took part in telephone interviews.
Dose: Ninety-one members of staff in the intervention arm received intervention training. Reach: The online tool was
accessed on 324 occasions by 27 clinicians. Reasons for non-use of the online tool were commonly that the patient
had already made a decision or that there was no online access in the clinic. Of the 32 women for whom there were
data available, fifteen from the intervention arm and six from the usual care arm were offered a choice of treatment.
Fidelity: Clinicians used the online tool in different ways, with some using it during the consultation and others
checking the online survival estimates before the consultation. Adaptation: There was evidence of adaptation when
using the DESIs. A lack of infrastructure, e.g. internet access, was a barrier to the use of the online tool. The brief
decision aid was rarely used. Mediators: Shared decision-making: Most patients felt able to contribute to decision-
making and expressed high levels of satisfaction with the process. Participants’ responses to intervention: Six patients
reported the DESIs to be very useful, one somewhat useful and two moderately useful.
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Conclusions: Clinicians who participated were mainly supportive of the interventions and had attempted some
adaptations to make the interventions applicable, but there were practical and engagement barriers that led to sub-
optimal adoption in routine practice.
Trial registration: ISRCTN46099296. Registered on 11 August 2016—retrospectively registered
Keywords: Breast cancer, Older women, Decision support, Shared decision-making, Intervention implementation,
Process evaluation
Contribution to the literature
 It is important to explore the implementation and
mechanisms of impact of interventions to understand how
the interventions may have led to the trial outcomes.
 Within this process evaluation of two decision support
interventions, clinicians were mainly supportive of the
interventions and had attempted some adaptations, but
implementation of some elements of the interventions was
limited.
 Practical and engagement barriers were found, supporting
previous studies that demonstrate difficulties in
implementing shared decision-making interventions.
 Team ‘buy in’ (“cognitive participation”) and practical
facilitation (“collective action”) of the interventions could be
targeted to improve implementation of these interventions
into routine clinical practice.
Background
The Bridging the Age Gap in Breast Cancer research
programme sought to improve treatment decision-making
for older women (≥ 70 years) with breast cancer by:
1) conducting an observational cohort study assessing
breast cancer outcomes of older women,
2) developing decision support interventions (DESIs)
to predict treatment outcomes and support shared
decision-making,
3) testing the DESIs in a cluster randomised trial.
Two DESIs were developed and tested [1–3]. In frailer
(defined as, those with decreased physiological reserve
and increased vulnerability to negative health outcomes)
older women (with oestrogen sensitive breast cancer),
one DESI supported the decision to have either primary
endocrine therapy (PET) or surgery with adjuvant ther-
apies (standard care). In fitter older women with high re-
currence risk breast cancer, the second DESI supported
the decision to have adjuvant chemotherapy after sur-
gery or not.
These treatment decisions are clinically important,
having a substantial impact on cancer and treatment
outcomes in older women [4–7]. Older women who
have standard care for their breast cancer have improved
overall and breast cancer-specific survival [3, 8] unless
they are very frail, when surgery may cause significant
harm [9, 10]. There are complex trade-offs to be made
because standard care (including surgery for all and
radiotherapy and chemotherapy if appropriate), whilst
oncologically superior, is associated with negative
quality-of-life impact and higher rates of complications
[9, 11]. In women over the age of 70, there is uncertainty
about the benefits of adjuvant chemotherapy due to the
lack of clinical trial data specific to this older age group
[12]. There is also evidence that rates of both surgery [9,
13] and chemotherapy [14] in this older age group vary
widely both between units in the UK and across Europe
[15, 16]. Decisions about treatment in these contexts can
therefore be challenging both for clinicians (we use this
term to include all types of healthcare professionals) and
patients and are often “preference sensitive” [17]. Shared
decision-making is particularly applicable in situations of
preference sensitive treatment decisions and DESIs aim
to support this process and improve the quality of treat-
ment decisions.
Summary of the trial
The trial was a multi-centre, parallel group, pragmatic,
cluster randomised controlled trial (cRCT) nested within
a larger cohort study of older women (> 70 years) with
early breast cancer ('Age Gap Cohort Study’ (ISRCTN
46099296)) [18]. In December 2015, 46 of the 57 Age
Gap cohort recruiting sites transitioned to a cRCT, with
half of these sites randomised to use of the DESIs to
support shared decision-making, and half to continue
usual care. The primary outcome was improvement in
quality-of-life. The findings from the cRCT are reported
in a separate publication [19].
The intervention
The DESIs were developed to ensure that the informa-
tion contained was accurate, relevant and desired by the
target population and written and presented optimally
for women of an older age demographic [1, 20, 21]. Each
DESI included three components: (1) an online risk pre-
diction model [2, 3, 21], (2) a brief decision aid [1] and
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(3) an information booklet [1] (see Fig. 1). Component 1:
The online tools were designed to help clinicians provide
personalised survival predictions for each treatment op-
tion (PET versus surgery with endocrine therapy; or
chemotherapy versus none after surgery). Clinicians
could also print out these details for their patients. Com-
ponent 2: The brief decision aids were designed to be
used within a consultation as a visual tool to support
shared decision-making. They contain frequently asked
questions and answers for each treatment option. They
aimed to help clinicians discuss the key information
about the treatment options with their patients, and help
patients think about what matters most to them about
the treatment options and convey this to their clinician.
Component 3: The information booklets provided more
detailed information about the treatment options and in-
cluded sections to help patients identify what mattered
most to them about each treatment option. Further de-
tails can be found at https://agegap.shef.ac.uk/.
Staff in the intervention arm sites were given the
DESIs to use as part of their usual clinical practice, re-
gardless of whether patients took part in the study or
not. Usual care sites were given information about the
background to the study but no intervention training (or
DESIs).
Intervention training
Staff received training before implementing the interven-
tion, and further support once implemented. Training
highlighted the importance of attitudes and skills for
shared decision-making, which are more important than
the DESIs themselves [22]. The DESIs act as a tool to
support shared decision-making [22]. As well as face-to-
face training, there were three instructional screencasts
and an animation available on the Age Gap website.
Two screencasts showed how to use each of the online
decision tools, i.e. for surgery with endocrine therapy or
PET and surgery with or without chemotherapy, and
one showed how the booklet and the brief decision aid
were developed and how to use them in a consultation.
These screencasts were designed to support the face-to-
face training; the content covered was the same as in the
face-to-face training. The animation demonstrated how
the DESIs were intended to be used with patients in the
Age Gap study, but that this was not prescriptive.
Process evaluation
Alongside the trial a detailed process evaluation was
undertaken. The Medical Research Council (MRC)
guidelines for the evaluation of complex interventions
were used to investigate the implementation and mecha-
nisms of impact of the intervention to explore the
process by which the intervention may have led to its ef-
fect or not [23]. The primary aims of the process evalu-
ation were to understand how the DESIs were used/
implemented, how acceptable and useful the DESIs were
to both staff and patients, and barriers and facilitators to
future implementation. We also sought to assess shared
decision-making as a short-term process through which
the interventions could improve quality-of-life by im-
proving confidence in making the best decision and re-
ducing regret about the choice made [18].
Methods
Regulatory approval
Ethics approval and research governance approval was
obtained (IRAS: 12 LO 1808). All patients and clinicians
gave written informed consent. The study was sponsored
by Doncaster and Bassetlaw Teaching Hospitals NHS
Foundation Trust.
Sites and sample
Sixteen sites, eight from each arm of the trial, were ran-
domly selected to take part in the process evaluation,
stratified by whether sites had low or high rates of re-
cruitment into the cohort study (Age Gap Cohort Study
(ISRCTN 46099296)).
Fig. 1 Details of the DESI components and suggested use; available at https://agegap.shef.ac.uk/
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Measures
Multiple methods of data collection were used to assess
the implementation of the intervention and its mecha-
nisms of impact. Implementation was assessed by exam-
ining dose, reach, fidelity and adaptations and
mechanisms of impact were assessed by examining me-
diators and participants’ responses (see Table 1).
To assess dose (to clinicians) and reach (to patients),
quantitative data from the intervention online tool log,
trial case report forms (see supplementary files 1 and 2)
and a bespoke (developed in-house) (Discussing treat-
ment options; see supplementary file 3) patient question-
naire were collected. Semi-structured interviews were
also used to ascertain dose and reach.
To assess fidelity, adaptation and participants’ re-
sponses to the DESI, we investigated how the interven-
tions were used and how acceptable and useful they
were. This was examined both from clinician
(adaptation) and patient (participants’ responses) points
of view, primarily using semi-structured interviews, but
also using a bespoke patient questionnaire. The Collab-
oRATE questionnaire [25] was used to assess the extent
of shared decision-making as a potential mediator of
the effect of the DESIs. For the purposes of this study,
we have assessed adaptation as alterations made to the
implementation of the DESIs by clinicians and partici-
pants’ responses were assessed by the patients' reactions
to the intervention.
Implementation guidance
Clinicians were encouraged to use the DESIs to support
usual practice, but we were not highly prescriptive in
how this should be done. The training materials in-
cluded an animation example of how the DESIs might
be used to encourage shared decision-making. It was ac-
knowledged that this may not always be possible.
Table 1 Summary of the methods of data collection used in the Age Gap Trial process evaluation




"the quantity of intervention implemented."
[23]
Clinicians: website login Record of the number of times the





"whether the intended audience [patients]
comes into contact with the intervention, and
how." [23]
a) Bespoke patient completed questionnaire
b) Patient semi-structured interviews
c) Bespoke case report forms
Details of the information received,
how it was used and how useful
patients found it. (See
supplementary file 3)
Exploration of patients' perceptions
of the information given, how it
was used and satisfaction with
decision-making.
Details of how and when clinicians
used the tools and reasons why
they did not. (see supplementary







Fidelity: (Clinicians and Patients)
"whether the intervention was delivered as
intended." [23]
a) Clinician semi-structured interviews
b) Patient semi-structured interviews
c) Clinician website access to personalised risk sheet
Exploration of clinicians' views of
the DESI, how it was used and their
views of its usefulness.
See above.
Record of the number of times the
personalised risk sheet was








"alterations made to [the] intervention [by the
clinician] in order to achieve better contextual
fit." [24]




"intermediate processes which explain
subsequent changes in outcomes." [24]
a) CollaboRATE [25]
b) Clinician semi-structured interviews
c) Patient semi-structured interviews








Participants’ (patients’) responses to
intervention:
"Participant responses to and interactions
with the intervention" [23]
a) Bespoke patient completed questionnaire







1Data were not collected from clinicians at usual care sites
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Clinicians were encouraged to use one or more of the
three elements of the relevant DESI during discussions
about treatment (see Fig. 1).
Procedure
Patients
Patient participants were recruited if they were willing to
be contacted about optional ‘further’ components of the
trial (ascertained in the main trial consent form) and
had had a discussion either about PET or surgery with
endocrine therapy, or about chemotherapy. Eligible pa-
tients were provided with an invitation pack (letter, in-
formation sheet, study reply form and reply envelope).
Patients who returned a completed study reply were
contacted to discuss any questions and to arrange a
face-to-face interview. Consent for the interview was
taken at the time of the interview.
Participants were sent the 6-week process evaluation
follow-up questionnaire when timing allowed. CollaboR-
ATE was collected as part of the main trial baseline
questionnaire.
Clinicians
Clinicians at intervention sites who could be involved in
a consultation to discuss treatment options were invited
to take part. Invitation packs (letter, information sheet,
consent form and reply envelope) were given to local re-
search staff to distribute to relevant clinical staff. Con-
sent forms included consent for participation in an
interview.
Data analysis
Descriptive statistics were used to analyse the question-
naires, case report forms and website log data. CollaboR-
ATE was scored using the CollaboRATE Top Score
method favoured for its ease of interpretation. Scores
range between 0 and 100 with higher scores representing
greater shared decision-making [25].
Patient and clinician interviews were audio-recorded,
pseudo-anonymised and transcribed verbatim. Data were
analysed using a thematic approach and organised using
the principles of the framework approach [26]. Initial
interview transcripts were read by two researchers (KL
and MB) discussed and codes agreed before developing
an analytical framework which was then applied to the
remaining interviews using NVivo 11 and charts were
then created using Microsoft Excel. Key categories were
identified using both a deductive approach, guided by
the topics in the interview guide, and inductive ap-
proach, based on the data. Codes relevant to the aims of
the process evaluation were selected and analysed to de-
scribe the themes in the data pertaining to reach, fidelity
and the mechanism of impact, i.e. mediators and the
participants' responses to the intervention (see Table 2).
Results
Patient sample
The sample was derived from 1339 trial participants, of
whom 495 were from process evaluation sites. Of these,
324 patients indicated on the trial consent form that
they would be happy to be approached for involvement
in other parts of the study and 165 patients were invited
to take part.
A total of 84 patients agreed to take part; however,
two patients withdrew. A total of 82 patients, median
age 75 (range 70–93), provided data although they did
not take part in every aspect of the process evaluation.
Seventy-three patient interviews were completed (see
Table 3). Of these, 35 were from intervention sites and
38 from usual care sites.
Clinician sample
Ten clinicians from six intervention sites took part in
telephone interviews. This included eight surgeons, one
oncologist and one nurse practitioner.
DESI implementation
“Dose”: take up of staff training
Ninety-one members of staff from process evaluation
sites in the trial’s intervention arm received intervention
training (see Table 4). Of these, 12 attended a standar-
dised offsite workshop, 77 attended onsite customised
training sessions, and six received telephone instruction
(see Fig. 2; some staff attended more than one training
Table 2 Patient interview themes
Final themes Codes MRC framework items mapped to codes
Treatment choice and decision-making Treatment choice and decision Reach, fidelity
Feelings about decision
Feelings about how decision was made Mediators
Use and usefulness of information What information was received Reach
How information/DESI was used Fidelity, participant response to intervention
Perceived usefulness of information Participant response to intervention
Impact of information Impact of information/DESI/discussion Participant response to intervention
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session). The amount of time spent in training varied
considerably. Workshops ran for approximately 120 min,
whilst the customised on-site training time ranged from
15 to 120 min with a median of 60 min.
“Reach”: use of DESIs with patients
The online tool data showed that the tool was accessed
on 324 occasions, from all eight process evaluation sites
by 27 clinicians (Table 5). It was not possible to tell
whether this was as part of training or contact with a
patient.
All eight intervention sites accessed and ran the online
tool to varying degrees. One site accessed it on only one
occasion whilst others ranged from 18 to 80 occasions
(median 45). Not all chose to download the personalised
sheet even though they had accessed the tool (Table 5).
Of the 82 patients who provided data in the process
evaluation, 41 (50%) were reported on the case report
form to have had a consultation in which either PET or
surgery with endocrine therapy (n=26, 31.7%) or chemo-
therapy (n=15, 18.3%) was discussed. Six (7.3%) had a
consultation about both, 20 (24.4%) had neither and case
report forms were not completed for the remaining 15
(18.3%) patients. See Table 6 for details.
Data from the case report forms show 15 patients from
intervention sites were offered a choice of PET or surgery
with endocrine therapy and five were not offered a choice.
Two of the 15 offered PET or surgery with endocrine
therapy were also offered chemotherapy. Six other patients
were offered a choice about chemotherapy. In the usual
care arm, six patients were offered a choice of PET or sur-
gery with endocrine therapy and six were not. Two pa-
tients were offered a choice of both PET or surgery with
endocrine therapy and chemotherapy, and eight others
were offered a choice about chemotherapy.
For the 15 with a choice of PET or surgery with endo-
crine therapy in the intervention arm, clinicians did not
report use of the online tool. It was used once to aid a
chemotherapy decision. The personalised sheet was
given to one chemotherapy patient but not given to any
of the PET or surgery with endocrine therapy patients
(see Fig. 3a and b). The top two reasons for non-use of
the online tool were that the patient had already made a
decision or that there was no online access in the clinic.
In one case, it was felt that the chemotherapy patient
was unsuitable. The brief decision aid was used once
during a chemotherapy consultation and one chemo-
therapy patient was given it to take away. Reasons for
non-use of the brief decision aid were the same as for to
the online tool. The booklet was used once during a
PET or surgery consultation and once in a chemother-
apy consultation, these patients were given it to take
away and one patient was given the PET or surgery with
endocrine therapy to take away (see Fig. 3b). Reasons for
non-use were again that the patient had already made
their treatment decision or that the booklets were not
available in the clinic. Completion of the case report
form to record DESI usage was incomplete with over
50% of the data missing.
During interviews, although all women remembered
receiving information, only some (18/35) of the women
recalled specifically receiving any of the DESI materials.
Furthermore, women reported receiving different ele-
ments of the DESI: ten of the 35 remembered the book-
let, five the brief decision aid and three the personalised
sheet. Only one chemotherapy patient remembered all
elements of the DESI.
“Fidelity”: intervention delivered as intended
Most of the clinicians interviewed were surgeons and
had mainly used the PET/surgery with endocrine ther-
apy DESI. All the surgeons interviewed had used the on-
line tool. The oncologist interviewed did not have access
to the online tool due to technical issues within the
Trust but was keen to use it when it was made available
to her. Some of the surgeons reported that they had
Table 3 Data collected and participant characteristics
Intervention arm Usual care arm
Patient interviews (n = 73) n = 35 n = 38
Median (range) age in years 76 (70–88) 73.5 (70–93)
Mean age in years 76.4 74.8
Questionnaires completed:
CollaboRATE (n = 18) n = 9 n = 9
Median (range) age in years 76.0 (72–83) 74 (72–93)
Mean age in years 76.0 75.7
Bespoke questionnaire (n = 24) n = 11 n = 13
Median (range) age in years 75.0 (70–79) 74 (70–93)
Mean age in years 74.2 75.6
Table 4 Training received by staff in process evaluation sites,
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used the booklets and/or brief decision aids, but they
also reported that they were aware that they were used
by the nurses with patients. Although the nurse practi-
tioner had not used the DESIs, she had observed consul-
tants and nurses using elements with patients during
consultations and offering them to patients to take away.
Clinicians reported using the online tool in two differ-
ent ways. Some went through the inputs (patient charac-
teristics) and outputs (treatment dependent survival
predictions) with the patient, and then offered or sent
the printout to patients. Others looked at the survival
predictions before the consultation. Survival estimates
calculated by the online tool were seen by the surgeons
as an objective basis upon which to base discussions of
the treatment options.
Clinicians also used the booklets and brief decision
aids in different ways with some going through them
during the consultation, others giving them to patients
to take away and others not using the DESIs. Findings
from both the patient and clinician interviews most fre-
quently found the brief decision aids were only rarely
used to support treatment choice discussion as intended
but were more usually given as a summary of the treat-
ment options.
“Yeah, the [pause] with regards to the booklet, and
the question and answer sheet (PET v Surgery brief
decision aid), I’ve sort of briefly described what
that’s about to the patient, but in general I will give
it to them to look at in their own time.” (Breast
surgeon)
“I: And do you remember...how it (PET v Surgery
brief decision aid) was used?
P: I think the doctor went through the options with
me and then I was given one of those to bring
home.” (78 years, breast-conserving surgery)
Some patients reported being given or sent the brief de-
cision aid and/or booklet to read at home, for others the
personalised print out and/or booklet were discussed and
used during the consultation and for one woman the brief
decision aid was used during the consultation. Very few
women used the values clarification exercise because they
felt a decision had already been made (either by them-
selves or through recommendation from the clinician).
“Adaptation”: to show how the intervention was tailored
From the clinician interviews, there was evidence of
adaptation of using each of the DESIs. Although all three
elements of the intervention were available for patients,
it was common for them to be given only one, usually
the booklet. Where the brief decision aid was used, it
was almost exclusively given as a means of providing a
summary of information and not as a prompt to engage
the patient in discussion before decision-making.
Some clinicians felt that providing the survival out-
comes information calculated by the online decision tool
was too “harsh” to give to the patient when the survival
predictions were poor. In this situation, clinicians mod-
erated this information and gave only the 2-year survival
predictions or explained the differences in survival be-
tween treatments rather than showing the absolute
values. (In designing the tools, this was the reason for in-
cluding 2 year outcomes so women with very short life
expectancy due to extreme old age or ill health would be
able to see some survival data).
Fig. 2 Flowchart to show number of staff trained and training mode. Asterisk indicates that some participants received additional telephone training
Table 5 Use of online tool
Number of times online tool accessed Number of times personalised risk sheet downloaded
Process evaluation sites (n = 8) 324 282 PET/surgery with endocrine therapy
42 chemotherapy
107 (from 5 sites; 3 sites did not download personalised sheets at all)
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Barriers and facilitators to use
During interviews, clinicians concentrated on the useful-
ness of the online tools and commented on how they
found these helped the discussion with patients. Clini-
cians found the survival predictions of the online tool
useful to inform their own clinical judgement about
treatment, as well as their patients’ opinions. They liked
that this was evidenced-based, with objective figures they
could present to their patients and sometimes the fam-
ilies. One surgeon had found it particularly helpful in re-
assuring a patient and her family that surgery was not
the best option.
However, comments were made by clinicians about
the current lack of validation of the data supporting the
online tools and they felt this may be a barrier to use
(validation had been performed but not published when
the trial commenced). For some, the logistics of using
the tool(s) within the consultation were a problem. The
lack of infrastructure, e.g. computers and printers within
the clinics, and the need for internet access were all
cited as barriers. Some felt that using the online tools
and/or the booklet and brief decision aid was, however,
potentially feasible within a consultation and was largely
down to personal organisation. However, one surgeon
felt it was not possible within the clinic appointment
duration. Some clinicians felt using the online tool dur-
ing the Multi-Disciplinary Team (MDT) meeting would
have been beneficial, but the logistics of having patient
information and computers available were again cited as
barriers. (However, many MDTs do now have access to
online algorithms during the MDT and use of PREDICT
is now commonplace so this should not be a problem
going forward.)
Clinicians felt that more detailed training in the use of
DESIs would allow them to be more effectively inte-
grated into their practice. During the course of the trial,
many sites had staff changes which led to poor
consistency and loss of expertise in using the DESIs.
This was cited as a barrier to implementation.
Clinicians commented that they felt the information
provided from the DESI elements gave the patient confi-
dence to engage in the decision-making process and feel
more content with their treatment decision. This had
encouraged some of these clinicians to continue using
the DESI tools. Some surgeons welcomed how the DESI
had changed the dynamic of the consultation and had
also made them more open-minded in considering treat-
ment options.
Those clinicians who used the booklets and brief deci-
sion aids commented that it was ‘custom and practice’
for the patients to be given large quantities of cancer-
related information (e.g. from breast cancer charities—
see below) and that the DESI information was likely to




Across both arms of the trial, most women reported be-
ing offered treatment options and were satisfied with the
way the decision was made. Many said they felt involved
in the decision-making process. Some stated specifically
that the information they received had given them the
confidence and knowledge to be involved. Women spoke
highly of clinicians: how they had given them time and
information, been supportive and listened to their pref-
erences. This view was further supported by the results
of the CollaboRATE questionnaire. Eighteen patients
completed a CollaboRATE questionnaire, nine in each
trial arm. All scored very highly, with the intervention
score range from 90 to 100 and usual care 93 to 100,
demonstrating high levels of satisfaction.
“Participants’ responses to intervention”
Eleven patients from the intervention arm completed the
bespoke questionnaire and seven reported the DESIs to
be very useful, one somewhat useful and two moderately
useful (one response was missing).
Women were given a vast quantity of generic breast
cancer information and this meant the DESIs were often
lost amongst it all. National cancer charities produce
comprehensive and appealing looking folders and gen-
eric treatment booklets which are easy for clinicians to
distribute but overwhelmed some patients who felt that
the information was irrelevant for them (not age or dis-
ease specific for them). Many women reported finding
Table 6 Numbers of patients from the case report form relating to patient choice with each treatment choice in process evaluation
study sites
Usual Care Intervention Total
N = 44 N = 38 N = 82
Consultation for: Both 2 (4.5%) 4 (10.5%) 6 (7.3%)
Surgery with endocrine therapy or PET only 10 (22.7%) 16 (42.1%) 26 (31.7%)
Chemotherapy only 11 (25.0%) 4 (10.5%) 15 (18.3%)
Neither 16 (36.4%) 4 (10.5%) 20 (24.4%)
Missing 5 (11.4%) 10 (26.3%) 15 (18.3%)
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a
b
Fig. 3 a Flowchart to show reach of DESI for PET or surgery with endocrine therapy in patients offered a choice of treatment. b Flowchart to
show reach of DESI for chemotherapy in patients offered a choice of treatment
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the information they received about their treatment use-
ful, though not expressly the DESIs. This usefulness was
predominantly to do with knowing what the treatment
would involve, being guided through the process and re-
ceiving confirmation of information also given verbally
by the clinicians. They felt the information enabled them
to more fully engage in the decision-making process.
They could understand what was being or had been dis-
cussed and the information gave reassurance about mak-
ing the right decision. For some, the combination of the
different information formats allowed them to feel in-
volved in the decision-making process. For instance,
some patients found that the written information
prompted further questions which they raised during
subsequent consultations.
Some women who were considering chemotherapy
and were shown output from an online tool (it was un-
clear whether this was the Age Gap tool or other tool
such as PREDICT) and used this information to either
accept or reject the option of chemotherapy. Only one
woman was sure it was the Age Gap online tool she had
seen. However, during the interviews it became clear
that not all the women understood the output from the
tool despite using the information to inform their
decision.
Patients made largely favourable comments about the
layout and presentation of all the information received.
Two women interviewed felt they received too much ir-
relevant, general information, not specifically the DESI,
and this was a barrier to using the information.
Discussion
This study examined the implementation of two DESIs
to support older women with breast cancer treatment
decisions. Despite the high number of patients recruited
to the cRCT, the reported implementation of some ele-
ments of the DESIs was limited at the intervention sites
participating in this process evaluation. Most women re-
ported receiving a lot of information about treatments,
both written and verbal. Generic (non-trial specific)
written information included booklets produced by char-
ities, locally provided leaflets as well as the trial specific
DESI materials. Some women described information as
being irrelevant which further justified our development
of age specific informational resources for this study.
Some women from intervention sites had not received
any elements of the DESI. The DESIs received positive
feedback from the clinicians interviewed, in particular
the online component, which is supported by the higher
usage than is reported in the case report forms. How-
ever, clinicians reported less use of the booklets and
brief decision aids, with some suggesting that perhaps
the breast nurses or research staff used these or provided
them to patients. Patient experiences of discussing
treatment options varied, both depending on their own
case (what options were available) and on the consulting
clinician. Most women felt involved in the decision-
making process, but the degree to which this was true
varied between individuals; some reported being given a
choice of treatments, whereas others reported a recom-
mended treatment plan.
This process evaluation was based on a randomly se-
lected sample of participating study sites, stratified for
recruitment rates into the cohort study as a measure of
research engagement. Mixed-methods data collection
was used, comprising web-log data, training participa-
tion, questionnaires and case report forms, and parallel
interviews with both patients and clinicians (surgeons,
nurses, oncologists). However, data capture and partici-
pation were also incomplete, highlighting some limita-
tions. Firstly, with regard to data capture, completion of
the case report forms documenting use of the DESIs was
poor with often more than half of report forms uncom-
pleted. During patient interviews, it was difficult to know
whether they were commenting on the DESIs or on
other information they received (e.g. from breast cancer
charities), thus providing a degree of uncertainty in our
findings. Secondly with regard to participation, there is
potential bias in the clinician sample particularly, as a
number of clinicians did not volunteer to participate,
and non-responders may view the DESIs less favourably.
Thirdly, regarding both data capture and participation,
the small amount of data relating to the chemotherapy
decision points to the need for further investigation par-
ticularly around decision-making for this treatment op-
tion. A further limitation is that this evaluation was part
of a large-scale research trial, and the findings may have
limited transferability for implementation efforts in rou-
tine practice [27].
However, the findings are consistent with other experi-
ences nationally and internationally about the difficulties
of implementing shared decision-making interventions
[22, 28]. The DESIs investigated here were rigorously de-
veloped with patient needs assessment, field testing and
clinician and patient input to consider their “fit” as sup-
portive interventions for normal practice. Although the
trial showed limited impact of the DESIs on quality-of-
life (the primary end point of the trial [19]), they did im-
pact on treatment choice and knowledge scores. The
process evaluation elements (italicised below) enable us
to identify where further intervention is required if
greater effects in improving quality-of-life and quality of
shared decision-making are to be achieved. This can also
be interpreted in relation to Normalisation Process The-
ory [29] (the core components are in quotation marks
below) about adoption of technology or interventions
into practice, as has been undertaken in relation to
shared decision-making previously [30, 31].
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There was good participation in training and in the
small number interviewed, favourable attitudes to the
purpose and elements of the DESIs, indicating reason-
able dose of the intervention and “coherence” or sense
making of the participants regarding implementation.
The exception to this coherence was one site that did
not use any aspect of the DESI following training. There
were however significant practical barriers, such as the
lack of online access in clinics and printer availability, as
well as the extent of other information also available to
patients, causing information overload and distraction
from the DESIs. These challenges impacted the fidelity
of the interventions, indicating problems in the clinical
teams which maybe explained with reference to two core
components, “cognitive participation” and “collective ac-
tion”, of the Normalisation Process Theory [29].
Cognitive participation is described as the “relational
work”, which in this study can be interpreted as the clin-
ical team’s initiation, organisation or re-organisation of
working practices (getting ‘buy in’), engagement with
and belief that staff can make a valid contribution to the
new practice. There was evidence of teams continuing
with their usual decision-making practices and making
little attempt to adjust to incorporate the DESIs.
Collective action is the “operational work” that
people do to endorse a complex intervention in
everyday practice. It describes how they are facilitated
to implement and how they use and experience the
intervention. It was clear that sites differed in the way
that they allocated resources and responsibility to the
delivery of the intervention with some making the re-
search staff alone responsible for the use of the DESIs
and not implementing them as part of usual practice
as intended. Turnover of team members often inter-
rupted the implementation. Practical challenges were
identified which need attention and support, including
efforts to resolve online access and printer availability.
There was evidence of adaptations made by clini-
cians, such as selecting which survival data were felt
most applicable, indicating consideration of the
“workability” of the intervention. Clinicians reported
that the use of the DESIs, most frequently the PET
or surgery with endocrine therapy, was associated
with shared decision-making and thus is a mediator
and indicates the inconsistent way staff used the
intervention in everyday practice (“contextual integra-
tion”). Skill development for shared decision-making,
through enhanced training, may be an area that can
be strengthened in future implementation efforts, to
enhance both “cognitive participation” and “collective
action” towards making these interventions more
“normal” in practice. We found some evidence of
favourable responses from patients, when the DESIs
were used. Formal appraisal and feedback, i.e.
“reflexive monitoring”, to clinicians was not part of
the complex intervention and thus could be strength-
ened also in future implementation efforts.
Further research is required regarding effective im-
plementation strategies for DESIs, particularly for
older patient groups. Specific interventions such as
shared decision-making skill development require
evaluation. Implementation work requires intensive
support [22]. It will also be important to explore how
to engage and support the clinical team better in
identifying ways of enhancing the “cognitive participa-
tion” and “collective action” amongst team members,
to achieve more successful implementation in
practice.
Conclusion
Whilst preliminary results suggest positive feedback
about the DESIs, from both patients and clinicians, lim-
ited use is also apparent from our data. Clinicians were
mainly supportive of the interventions and had
attempted some adaptations to make the interventions
more applicable. However, there were still considerable
practical barriers that led to limited adoption of the in-
terventions in routine practice. These barriers need to
be addressed if older patients are to be supported to
make effective decisions about important health care
conditions and to achieve best outcomes in their per-
sonal situation.
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